Table 1.
Clinicopathologic factors related to bone metastases in 181 HCC patients
| HCC Bone Metastases | |||||
|---|---|---|---|---|---|
| Clinicopathologic Parameters | No. of Cases | Negative (n = 138) |
P Value (P1, P2)§ |
||
| A* (n = 113) | B* (n = 25) | Positive (n = 43) |
|||
| Age (y) | |||||
| ≤ 60 | 153 | 94 (83.2%) | 21 (84.0%) | 38 (88.4%) | P1 = 0.422 |
| > 60 | 28 | 19 (16.8%) | 4 (16.0%) | 5 (11.6%) | P2 = 0.434 |
| Gender | |||||
| Female | 25 | 15 (13.3%) | 4 (16.0%) | 6 (14.0%) | P1= 0.912 |
| Male | 156 | 98 (86.7%) | 21 (84.0%) | 37 (86.0%) | P2 = 0.540 |
| HBsAg | |||||
| Negative | 37 | 22 (19.5%) | 5 (20.0%) | 10 (23.3%) | P1= 0.601 |
| Positive | 144 | 91 (80.5%) | 20 (80.0%) | 33 (76.7%) | P2 = 0.755 |
| AFP (ng/mL) | 181 | ||||
| ≤ 20 | 48 | 28 (24.8%) | 7 (28.0%) | 13 (30.2%) | P1= 0.544 |
| 20 – 400 | 59 | 39 (34.5%) | 9 (36.0%) | 11 (25.6%) | P2 = 0.648 |
| ≥ 400 | 74 | 46 (40.7%) | 9 (36.0%) | 19 (44.2%) | |
| Cirrhosis | |||||
| Absence | 45 | 30 (26.5%) | 6 (24.0%) | 9 (20.9%) | P1= 0.469 |
| Presence | 136 | 83 (73.5%) | 19 (76.0%) | 34 (79.1%) | P2 = 0.768 |
| Satellite Lesion | |||||
| Absence | 127 | 94 (83.2%) | 13 (52.0%) | 20 (46.5%) | P1< 0.001※ |
| Presence | 54 | 19 (16.8%) | 12 (48.0%) | 23 (53.5%) | P2 = 0.662 |
| Tumor Size (cm) | 181 | 6.04 ± 3.57 | 6.92 ± 3.34 | 7.26 ± 3.19 |
P1= 0.051 P2 = 0.676 |
| Margins | |||||
| Clear | 79 | 56 (49.6%) | 10 (40.0%) | 13 (30.2%) | P1= 0.030※ |
| Involved | 102 | 57 (50.4%) | 15 (60.0%) | 30 (69.8%) | P2 = 0.412 |
| Vascular invasion | |||||
| Absence | 95 | 70 (61.9%) | 9 (36.0%) | 16 (37.2%) | P1= 0.006※ |
| Presence | 86 | 43 (38.1%) | 16 (64.0%) | 27 (62.8%) | P2 = 0.921 |
| Portal Vein Thrombosis | |||||
| Absence | 153 | 97 (85.8%) | 20 (80.0%) | 36 (83.7%) | P1= 0.739 |
| Presence | 28 | 16 (14.2%) | 5 (20.0%) | 7 (16.3%) | P2 = 0.698 |
| Hilar lymph nodes | |||||
| Absence | 170 | 109 (96.5%) | 23 (92.0%) | 38 (88.4%) | P1= 0.066 |
| Presence | 11 | 4 (3.5%) | 2 (8.0%) | 5 (11.6%) | P2 = 0.488 |
| UICC T stage | |||||
| T1 | 91 | 74 (65.5%) | 7 (28.0%) | 10 (23.3%) | P1< 0.001※ |
| T2 | 38 | 17 (15.0%) | 8 (32.0%) | 13 (30.2%) | P2 = 0.856 |
| T3 | 52 | 22 (19.5%) | 10 (40.0%) | 20 (46.5%) | |
| Edmondson grade | |||||
| Low (I/II) | 118 | 81 (71.7%) | 15 (60.0%) | 22 (51.2%) | P1= 0.016※ |
| High (III/IV) | 63 | 32 (28.3%) | 10 (40.0%) | 21 (48.8%) | P2 = 0.481 |
| CXCR4 | |||||
| Negative | 90 | 70 (61.9%) | 11 (44.0%) | 9 (20.9%) | P1< 0.001※ |
| Positive | 91 | 43 (38.1%) | 14 (56.0%) | 34 (79.1%) | P2 = 0.044※ |
* A: HCC without metastasis; B: Distal metastatic HCC without bone involvement.
§ P1: Statistical analysis of HCC patients with bone metastases (n = 43) and without metastases (n = 113).
P2: Statistical analysis of distal metastatic HCC without bone involvement (n = 25) and HCC patients with bone metastases (n = 43).
# Student t test.
※ Significant P value.